Helius Medical Technologies has a Cash Ratio of 0.50. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Helius Medical Technologies's Cash Ratio or its related term are showing as below:
HSDT'
s Cash Ratio Range Over the Past 10 Years
Min: 0.39 Med: 1.4 Max: 7.32
Current: 0.5
During the past 11 years, Helius Medical Technologies's highest Cash Ratio was 7.32. The lowest was 0.39. And the median was 1.40.
HSDT's Cash Ratio is ranked worse than 68.5% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 1.09
vs HSDT: 0.50
Helius Medical Technologies Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Helius Medical Technologies's Cash Ratio
For the Medical Devices subindustry, Helius Medical Technologies's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helius Medical Technologies's Cash Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Helius Medical Technologies's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Helius Medical Technologies's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helius Medical Technologies (NAS:HSDT) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Helius Medical Technologies Cash Ratio Related Terms
Thank you for viewing the detailed overview of Helius Medical Technologies's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HSDT has been successfully added to your 